UNSPSC 51371906: Levacetylmethadol or levomethadyl acetate

This classification denotes an opioid receptor agonist with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3B637Y991, chemically known as 3-heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3s,6s)-(-)- (8ci) but generally known as levacetylmethadol, which bears US NIH Compound Identifier 15130. European Medicines Agency schedules Levacetylmethadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08451MIG.

UNSPSC 51371906 Levacetylmethadol or levomethadyl acetate is a Commodity code that in recent state and local procurement shows minimal direct activity aligned with its nominal scope; instead, the opportunities tagged to this code reflect broader pharmaceutical procurement addressing opioid response, addiction treatment infrastructure, and generic drug distribution across state health systems and county health departments. State and local governments are buying naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive solicitations and cooperative purchasing mechanisms rather than levacetylmethadol specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The pharmaceutical procurement spans community health initiatives, state employee and retiree health plans, and multi-jurisdictional government facilities.

Recent activity centers in Florida and Minnesota, with Texas HHS conducting early-stage market intelligence. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the county community health building in Sanford, with all shipping included in vendor bids. Minnesota's MMCAP issued an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026, targeting multiple awards across participating state and local facilities with pricing weighted at 75 percent and administrative compliance at 25 percent. Texas HHS posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. None of these solicitations directly target levacetylmethadol; the code assignment appears to reflect the pharmaceutical category rather than the specific active ingredient.